Society of Diabetic Nephropathy Prevention Journal of Preventive Epidemiology 2476-3934 6 1 2021 01 01 Lupus anticoagulant in patients with COVID-19: A review e07 e07 10.34172/jpe.2021.07 EN Milad Nazari Sabet https://orcid.org/0000-0002-1989-2657 Elham Ahmadipour https://orcid.org/0000-0002-9662-2183 Shadi Zamansaraei https://orcid.org/0000-0003-3753-4631 Journal Article 10.34172/jpe.2021.07 2021 04 22 2021 06 18 Introduction: Coronavirus disease 2019 (COVID-19) is characterized by a pro-coagulant state that can lead to fatal thromboembolic events. A high prevalence of lupus anticoagulant has been shown in several studies that may at least partially explain the pro-coagulant profile of COVID-19. However, the relation between COVID-19 and lupus anticoagulant is arguable, and no study has clearly evaluated the concussion of lupus anticoagulant on mortality. Methods: We searched the articles that related to lupus anticoagulant and patients with COVID-19. Two authors independently reviewed the search results to select English language articles discussing lupus anticoagulant in patients with COVID-19. Results: Recent studies found conflicting results about the association between lupus anticoagulant and thromboembolic complications of COVID-19. Studies documented a high prevalence of lupus anticoagulants as well as several other studies. Patients with lupus anticoagulants were older, and their C-reactive protein, high-sensitivity troponin, and activated partial thromboplastin time (aPTT) were significantly higher than patients without lupus anticoagulants. Conclusion: Those started on therapeutic anticoagulation showed more severe and complicated involvements and a higher risk of death. According to our results, lupus anticoagulant is highly prevalent among hospitalized COVID-19 patients. Whether these antibodies promote a hypercoagulable state or they are merely a coincidence, epiphenomenon needs further evaluation.